Dynacure announces publication of Hierarchical Bayesian modelling of disease progression in Orphanet Journal of Rare Diseases
Bayesian statistical approach based on natural history study could address clinical trial design challenges in centronuclear myopathy
News provided by
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the publication of a paper entitled,
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy (CNM). The paper was published this month in Orphanet Journal of Rare Diseases, a scientific, peer-reviewed publication and can be accessed here.
The Assura fund is supporting groups such as Motherwell, which runs wellbeing walks in Winsford MORE than £10,000 has been awarded to three good causes looking to provide additional support people in mid Cheshire through the pandemic. Assura, which runs Dene Drive Primary Care Centre in Winsford, has announced the first organisations that have been successful in bidding for a slice of its new Community Fund. The fund was created to support charities looking to improve the health and wellbeing of people in the areas surrounding its medical centres. For services supporting Winsford residents Assura has awarded £4,600 to Transformation for Veterans, £3,919 to Motherwell and £2,466 to the Neuromuscular Centre.